Fingerprint
Dive into the research topics of 'Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers
Karin Jordan, Olaf Kellner, Thomas Kegel, Hans Joachim Schmoll, Axel Grothey
Research output: Contribution to journal › Article › peer-review
30
Scopus
citations